Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A particular immunosuppressant.

Etymologies

Sorry, no etymologies found.

Examples

  • The FDA is about to withdraw Avastin as a treatment for women with terminal breast cancer, and then there's a drug that most readers probably haven't heard of, called pixantrone.

    The FDA and Slower Cures

  • During the Class Period, defendants misled investors concerning the results of a Phase III clinical study ( "PIX-301") of a drug the Company was developing called pixantrone for the treatment of Non-Hodgkin's Lymphoma ( "NHL"), as well as other cancers.

    TradingMarkets

  • During the Class Period, defendants misled investors concerning the results of a Phase III clinical study ( "PIX-301") of a drug the Company was developing called pixantrone for the treatment of Non-Hodgkin's Lymphoma ( "NHL"), as well as other cancers.

    TradingMarkets

  • The real victims are the patients with no attractive options who needlessly suffer when the government delays drugs like pixantrone.

    The FDA and Slower Cures

  • As destructive, the FDA went out of its way to railroad pixantrone and make an example of the drug's maker, Cell Therapeutics, in order to send another warning to the drug industry to jump through the right bureaucratic hoops.

    The FDA and Slower Cures

  • For drugs like pixantrone, where success is less certain and budgets are limited, even large drug makers will run a single controlled trial—so that if the drug does succeed, it complies with FDA regulations.

    The FDA and Slower Cures

  • In this case, enrollment was hobbled because pixantrone wasn't a "sexy" drug—in 2004, there was minimal data about its effectiveness and thus minimal interest from U.S. oncologists or hematologists.

    The FDA and Slower Cures

  • The agency's veto came not because pixantrone failed in a clinical trial—in fact, it was a qualified success.

    The FDA and Slower Cures

  • Later, discussing a technical detail of pixantrone's trial design, he emphasized that "I think we as an oncology community have to get that point across to drug developers, because we will continually have applications with very marginal results."

    The FDA and Slower Cures

  • His excuse for rejecting pixantrone was that original Special Protocol Assessment.

    The FDA and Slower Cures

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.